Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement Regarding Nomination of Robert F…
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
BIO Released the Following Statement After…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO Statement on Lawsuit Over 340B Rebates
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
All Press Releases
  • Show All
Search
Results
Event Tags
March 2, 2022
The following statement can be attributed to BIO’s President and CEO Dr. Michelle McMurry-Heath in response to the ongoing conflict in Ukraine and the organization’s efforts to help in humanitarian relief: “The conflict in Ukraine and violence…
February 15, 2022
The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo:  “BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an…
February 15, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement after Dr. Robert Califf was confirmed by the Senate to lead the Food and Drug Administration (FDA): “We congratulate Dr…
February 14, 2022
Current pipeline “insufficient” to meet the threat of AMR, policy reforms critically needed   The Biotechnology Innovation Organization (BIO) today released a new report examining antibacterial innovation and the current pipeline for new…
February 2, 2022
The following statement can be attributed to BIO's President and CEO Dr. Michelle McMurry-Heath: “President Biden has long been a champion of research to end cancer. He reaffirmed that commitment today with the relaunch of the "Cancer Moonshot." …
January 20, 2022
Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on bioscience economic development best practices, “Driving the Bioscience Economy Forward During…
January 13, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to…
November 19, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today…
November 16, 2021
The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical…
November 4, 2021
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the following statement: "Last week, Democratic leaders announced they had reached a drug pricing “deal.” We wanted to see the details before…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.